首页> 外文OA文献 >Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC

【2h】

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC

机译：一名患有RRx-001耐药和T790M阴性NSCLC的RRx-001预处理患者对卡铂的部分反应

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

AI期刊论文写作 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Carter Corey A.; Oronsky Bryan; Caroen Scott; Scicinski Jan; Cabrales Pedro; Degesys Aiste; Brzezniak Christina;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC [J] . Corey A. Carter, Bryan Oronsky, Scott Caroen, Respiratory Medicine Case Reports . 2016,第2期

机译：一名患有RRx-001耐药和T790M阴性的NSCLC的RRx-001预处理患者对卡铂的部分反应
2. A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to Platinum Doublet [J] . Hope Cottrill, Stephanie Cason, Scott Caroen, Journal of Investigative Medicine High Impact Case Reports . 2018,第4期

机译：一名复发铂难治性卵巢癌患者，对RRx-001增敏对Doublet药物有部分反应
3. A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient after Priming with RRx-001 [J] . Bryan Oronsky, Scott Caroen, Karen Zeman, Clinical Medicine Insights: Oncology . 2016,第9期

机译：RRx-001引发的耐药小细胞肺癌患者对重新引入化疗的部分反应
4. Evaluation of Serum protein mass spectrometry technology to identify NSCLC patients with tumor response to gefitinib [C] . PEIZi-qi, HU Shou-xi, ZHAO Yun, 2011 Asia-Pacific Conference of tumor biology and medicine . 2011

机译：评估血清蛋白质谱技术以鉴定对吉非替尼有肿瘤反应的NSCLC患者
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC [O] . Corey A. Carter, Bryan Oronsky, Scott Caroen, 2016

机译：RRx-001耐药和T790M阴性NSCLC的RRx-001预处理患者对卡铂的部分反应
7. P2-224: A multicenter phase II randomized study of paclitaxel (P) and carboplatin (C) versus oral vinorelbine (oV) and carboplatin (C) as second-line treatment in patients with non-small cell lung cancer (NSCLC) pretreated with non-platinum based chemotherapy [O] . Agelidou A, Agelaki S, Chandrinos V, 2007

机译：P2-224：紫杉醇（P）和卡铂（C）与口服长春瑞滨（oV）和卡铂（C）作为二线治疗非小细胞肺癌（NSCLC）患者的二线治疗的多中心II期随机研究非铂类化学疗法

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC

著录项

引文网络

相似文献

相关主题

期刊订阅